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Patients with systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) display
increased levels of type I interferon (IFN)-induced genes. Plasmacytoid dendritic cells
(PDCs) are natural interferon producing cells and considered to be a primary source of
IFN-α in these two diseases. Differential expression patterns of type I IFN-inducible tran-
scripts can be found in different immune cell subsets and in patients with both active
and inactive autoimmune disease. A type I IFN gene signature generally consists of three
groups of IFN-induced genes – those regulated in response to virus-induced type I IFN,
those regulated by the IFN-induced mitogen-activated protein kinase/extracellular-regulated
kinase (MAPK/ERK) pathway, and those by the IFN-induced phosphoinositide-3 kinase (PI-
3K) pathway. These three groups of type I IFN-regulated genes control important cellular
processes such as apoptosis, survival, adhesion, and chemotaxis, that when dysregulated,
contribute to autoimmunity. With the recent generation of large datasets in the public
domain from next-generation sequencing and DNA microarray experiments, one can per-
form detailed analyses of cell-type specific gene signatures as well as identify distinct
transcription factors (TFs) that differentially regulate these gene signatures. We have per-
formed bioinformatics analysis of data in the public domain and experimental data from
our lab to gain insight into the regulation of type I IFN gene expression. We have found
that the genetic landscape of the IFNA and IFNB genes are occupied by TFs, such as
insulators CTCF and cohesin, that negatively regulate transcription, as well as interferon
regulatory factor (IRF)5 and IRF7, that positively and distinctly regulate IFNA subtypes. A
detailed understanding of the factors controlling type I IFN gene transcription will signif-
icantly aid in the identification and development of new therapeutic strategies targeting
the IFN pathway in autoimmune disease.
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INTRODUCTION
Patients with autoimmune diseases, such as systemic lupus ery-
thematosus (SLE) and Sjögren’s syndrome (SS), display increased
expression of type I interferon (IFN)-induced genes. Plasmacy-
toid dendritic cells (PDC), as natural IFN-producing cells, are
considered to be a primary source of IFN-α in such diseases (1,
2). The type I IFN family consists of multiple members, includ-
ing 14 IFN-α subtypes, -β, -ε, -κ, -ω, -δ, and -τ. These members
may have autocrine effects on the IFN-producing cells them-
selves, such as PDCs, and paracrine effects on neighboring cells, as
well as systemic effects on distant immune cells (3). IFNs can be
added directly to cell cultures and molecular profiling performed
to understand their biologic effect. For instance, the direct treat-
ment of peripheral blood mononuclear cells (PBMCs) with 0.6 pM
of IFN-α, -β, or IFN-ω led to the increased expression of about
200 genes (4). Broadly speaking, an IFN gene signature should
include all of these genes. These genes can be functionally classi-
fied into antiviral pathways, apoptosis control, cell surface receptor
expression, chemokine/cytokine expression, and components of
IFN signaling pathways.
Although methods of bioinformatics analysis are not yet inten-
sively used in immunology research, the field is changing fast
and significant information can now be obtained from the pub-
lic domain for the analysis of mechanisms controlling type I IFN
gene expression. This report explores several elements of transla-
tional bioinformatics analysis, specifically addressing the biologi-
cal questions relevant to how type I IFN expression is regulated in
autoimmune disease. We collected publically available microarray
gene expression datasets in Gene Expression Omnibus (GEO) at
the National Center for Biotechnology Information (NCBI) and
performed data mining and pathway analysis. With the grow-
ing datasets in public repository that are shared in the research
community, the integrative analysis of experimental data and dis-
ease profiling data sets has become an important approach to our
understanding of autoimmune disease pathology at the molecu-
lar level. In this study, we have also used human datasets from
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the Encyclopedia of DNA Elements (ENCODE) to understand the
epigenetic codes that control the type I IFN gene cluster. This infor-
mation can be used as a reference to guide future experiments that
focus on epigenetic changes in more relevant human immune cell
populations such as monocytes and dendritic cells. Understanding
the regulation and epigenetic control of type I IFN expression will
be useful for the development of new therapeutic interventions
targeting the IFN pathway in autoimmune disease.
MATERIALS AND METHODS
MATERIALS
Gene expression microarray data were retrieved from NCBI’s GEO
through series accession numbers GSE17762 and GSE10325. Data
were loaded with GEO query and limma R packages from the Bio-
conductor project. Alternatively, GEO2R, an interactive web tool,
was used. Next-generation sequencing datasets from multiple cell
lines and cell types were retrieved from the ENCODE Project1.
METHODS
In brief, for the analysis of microarray data, gene symbols and
value of log fold changes for individual genes were extracted
from NCBI’s GEO and Ingenuity IPA software was used to per-
form pathway analysis. For next-generation sequencing datasets,
ENCODE offers a few software tools for analyzing the data. One
relevant tool is factor book, which organizes all the informa-
tion associated with individual transcription factors (TFs) (5).
Although useful, it should be noted that the current lack of infor-
mation on human primary immunocytes limits one’s ability to
analyze individual genes/gene clusters and therefore limits the
value and/or relevance of some of these datasets.
The following information provides a brief summary of
methods used for the analysis of next-generation sequenc-
ing data. For example, the epigenome analysis of the
IFNA gene cluster was performed using a variety of
resources for data visualization. In brief, the genetic region
was located and retrieved in UCSC genome browser
using URL http://genome.ucsc.edu/cgi-bin/hgTracks?position=
chr9:21000000-21550000. Methylated/unmethylated CpGs data
was retrieved using Methylation-sensitive restriction enzyme
sequencing (MRE-seq) and MeDIP-seq loaded from http://
genome.ucsc.edu/cgi-bin/hgTrackUi?g=ucsfBrainMethyl. Methyl
Reduced Representation Bisulfite Sequencing (RRBS) tracks
were loaded from http://genome.ucsc.edu/cgi-bin/hgTrackUi?g=
wgEncodeHaibMethylRrbs, samples used include all cells in the
following list: http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=
342586899&c=chr9&g=wgEncodeRegTfbsClusteredV2. Histone
modification data, including H3K4me3 was loaded from
http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=342586899&c=
chr9&g=wgEncodeReg. For the analysis of CTCF and other rel-
evant TFs, we selected TFs and cell types by adding tracks from
http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=wgEnco
deAwgTfbsUniform. TF binding peaks were either calculated using
ENCODE pre-processed data with a False Discovery Rate of 1% or
mapped to human genome hg37 using CLC Genomics Workbench
1http://genome.ucsc.edu/ENCODE/
software 5.5, followed by peak calling using Model-based Analysis
for ChIP-Seq (MACS).
RESULTS AND DISCUSSION
RELATIONSHIP BETWEEN THE TYPE I IFN GENE SIGNATURE AND
CLINICAL AUTOIMMUNE BIOMARKERS
We have performed an in depth bioinformatics analysis of genes
regulated by type I IFNs, as well as the mechanisms controlling
type I IFN expression, in autoimmune diseases using publically
available datasets. In many cases, we found that IFN-induced
genes directly explain the presence of clinical biomarkers that
appear in patients with autoimmune diseases. For example, we
found that IFN-α increases the expression of interleukin (IL)-
15 and its receptor IL-15Rα in PBMCs. IL-15, that is primarily
expressed by activated monocytes and dendritic cells, binds to IL-
15Rα (CD359) on accessory cells and is trans-presented to T cells
that express functional IL-15Rα, composed of IL-2/15Rβ (CD122)
and γc chains. Several groups have reported elevated IL-15 levels
in the sera of SLE patients, however, the functional consequence
of IL-15Rα activation in SLE remains to be studied (6). In addi-
tion to IL-15 and IL-15Rα, IFN-β moderately upregulates IL-7
and CD59 transcripts in PBMCs. IL-7 is a survival factor for
naïve, early effector, and memory CD4+ and CD8+ T cells. It
is primarily produced by fibroblastic reticular cells (FRCs), a mes-
enchymal cell population found in the stromal environment of
lymphoid organs. In SLE patients, soluble (s)IL-7R concentrations
were found to be elevated in the serum and raised levels of sIL-7
were detected in patients with lupus nephritis (LN) that reflected
activation of kidney tissue cells (7). Receptor blockade by anti-IL-
7Rα in MRL-Faslpr lupus mice resulted in alleviation of dermatitis,
lymphadenopathy, splenomegaly, and total serum IgG2a; yet, only
a marginal reduction in IgG2a autoantibodies was found (8).
CD59 are glycosylphosphatidylinositol-anchored proteins with
complement inhibitory properties that prevent the terminal poly-
merization of the membrane attack complex. Increased numbers
of CD55- and CD59-lymphocytes and CD59-granulocytes were
found in SLE patients as compared with controls (9).
PATHWAY ACTIVATION BY TYPE I IFNs
Type I IFNs may play a pathological role in autoimmune disease
through their ability to regulate key signaling pathways impor-
tant in the innate immune response. For instance, we found that
IFN-α upregulates the expression of Toll-like receptors (TLR)-3
and TLR-7, as well as the critical cofactor myeloid differentiation
primary response protein 88 (MyD88). IFN-α also enhances the
expression of interferon regulatory factor (IRF)2, which compet-
itively inhibits IRF1-mediated transcriptional activation of IFNA
and B genes. As compared to IFN-α, the effect of IFN-β on
gene expression extends to TLR-1, TRAF/TANK, IRF4, and IRF1.
We also found in our analysis that the human dual specificity
mitogen-activated protein kinase kinase 5 (MAP2K5) can be up-
regulated by IFN-α/IFN-β and mitogen-activated protein kinase
kinase 8 (MAP3K8) can be induced by IFN-β. Since p38 MAPK
acts up-stream of type I IFN-induced STAT (signal transducers and
activators of transcription) 1 signaling (10, 11), the up-regulation
of MAP3K8 or MAP2K5 may provide further hints toward the
biologic effects of type I IFN on cells. For example, MAP3K8 has
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been shown to promote the production of tumor necrosis fac-
tor (TNF)-α and IL-2 during T lymphocyte activation. It is also
known that addition of IFN-αwith anti-CD3 antibodies results in
enhanced T helper (Th)1 responses that associate with enhanced
phosphorylation of STAT1 (12).
It is well-known that IFN-α has pro-apoptotic effects in many
cancer cell types including myeloma (13), renal cell carcinoma
(14), and glioma (15). It is also known that monocytes stimulated
with IFN-α express functional TNF-related apoptosis-inducing
ligand (TRAIL), which is capable of killing myeloma cells (16).
IFN-α also increases the expression of functional FasL exclusively
on natural killer (NK) cells (17). The functional clustering of
genes regulated by IFN-β, using DAVID tools, revealed a num-
ber of genes that control apoptosis, including caspase 1, 8, and
10, TRAIL (TNFSF10), and FADD [Fas (TNFRSF6)-associated via
death domain].
THE TYPE I IFN GENE SIGNATURE IN SLE B CELLS AND T CELLS
Disease biomarkers or disease gene signatures provide important
clues for our understanding of disease pathogenesis and aid in
the identification and development of new therapeutic strategies
for treatment. High-throughput screening technologies, such as
DNA microarrays, have been used to profile disease signatures
in PBMCs from SLE patients (18), and subsequently, in specific
subsets such as monocytes, neutrophils, T cells, and B cells. The
presence of a type I IFN gene signature in PBMC of SLE patients
has been recognized for nearly 35 years now (19). However, not
all IFN-inducible genes that have been identified by in vitro assays
can be detected in vivo in PBMCs isolated from SLE patients.
About 20 IFN-inducible genes were consistently found to be highly
expressed in PBMC from SLE patients (18). In our analysis of
SLE B and T cells, we found that approximately 10 IFN-inducible
genes were consistently and highly expressed. The gene transcrip-
tional signatures that appear to overlap between cell types include
Mx1, ISGF-3, PRKR, IFIT1, and IFI44 in cells that have been either
exposed to type I IFNs in vivo or in vitro. This gene signature has
been used as a readout for the type I IFN bioassay and is consid-
ered a measure of the “IFN-α activity score” in patients with SLE
and other inflammatory or autoimmune diseases (19, 20).
Intensive pathway analyses with KEGG2, BioCarta3, and Gen-
MAPP4 have shown up-regulated activation markers on SLE T cells
and genes that correlate with STAT1 expression (21). Using IPA5
analysis of independent datasets, we also found groups of genes
in the network that strongly correlate with STAT1, suggesting a
persistent and strong effect downstream of type I IFNs in SLE
T cells. Furthermore, IFN response factor consensus sequences
(ISREs) can be found up-stream of the start sites of each of the
genes in the type I IFN gene signature. Our independent analysis
also indicated groups of up-regulated genes in SLE T cells that
can be modulated by STAT4. Genome-wide mapping of STAT4
and IRF 5 occupancy in immune cells from SLE patients by
chromatin immunoprecipitation combined with next-generation
sequencing (ChIP-seq) revealed the possible cooperation of high
2www.genome.ad.jp
3www.biocarta.com
4www.genmapp.org
5www.ingenuity.com
mobility group-I/Y, specificity protein 1, and paired box 4 with
IRF5 and STAT4 in transcriptional regulation (22). As noted above,
IFN-regulated pathways derived from in vitro data do not always
align with microarray datasets obtained from primary cells of
SLE patients. In this regard, short-term IFN treatment has been
shown to promote apoptosis signaling via TRAIL pathways. How-
ever, anti-apoptotic signatures, including elevation of caspase 8
and FADD-like apoptosis regulator (CFLAR), were identified in
lupus T cells (21). Our bioinformatics pathway analysis identified
additional genes, such as BIRC5, that participate in the B cell anti-
apoptotic pathway in cells isolated from SLE patients. Given that
apoptosis and the clearance of apoptotic material have been impli-
cated in SLE pathogenesis, further research detailing the in depth
analysis and mapping of these anti-apoptotic pathways in PBMC
subsets will be of significant importance to our understanding of
SLE pathogenesis.
GENETIC LANDSCAPE OF THE TYPE I IFN CLUSTER
The human type I IFN gene cluster spans approximately 450 kb
on chromosome 9p22. IFNB and IFN ε define the boundaries of
the cluster, with all other type I IFN genes, except IFNk, dis-
tributed between these borders. This gene cluster also contains
KLHL9, which is a substrate-specific adaptor of the BCR (BTB-
CUL3-RBX1) E3 ubiquitin ligase complex that functions in cell
division. Studies of virus-induced type I IFN production in murine
fibroblasts indicates the presence of an immediate-early response
gene, IFNA4, which is induced rapidly and without the need for
ongoing protein synthesis, and IFNA2, 5, 6, and 8, that display
delayed induction, are induced more slowly, and require cellu-
lar protein synthesis. In CpG-stimulated human PDCs, IFNA5,
IFNA10, IFNA4, 1/13, 21, 14, 16, and 6 transcription can be
detected within 2 h. IFN21 and IFNA16 levels are dramatically up-
regulated further after 8 h suggesting an efficient positive feedback
loop regulating expression of these two genes. Recent analysis of
data from the ENCODE Consortium suggests that this important
gene cluster may be controlled by epigenetic regulation supporting
new mechanistic insight and a basis for the design of experiments
focused on this aspect of type I IFN gene regulation.
Methylation
Indeed, there has already been significant data in the litera-
ture to support the mechanism(s) of epigenetic regulation in
autoimmune diseases. In particular, DNA from SLE T cells was
found to be less methylated than control DNA from normal T
cells by measuring the cellular deoxymethylcytosine content (23).
Interestingly, non-T cells from lupus patients displayed normal
DNA methylation levels (24). Decreased DNA methyltransferase
(DNMT) activity in lupus T lymphocyte nuclear proteins was
considered to be responsible for the observed DNA hypomethy-
lation in lupus T cells. Patients with lupus had significantly
lower levels of DNMT1 mRNA, but not DNMT3A or DNMT3B,
as compared with healthy controls (25). A preliminary analysis
of microarray data from immature monocyte-derived dendritic
cells (MDDCs) revealed that they express abundant amounts
of DNMT1, which is downregulated after LPS stimulation. The
methylation status of DNA from SLE PDCs and the levels of
DNMT1 expression in this important IFN-α producing cell type
are not currently known.
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In general, hypermethylation in the promoter of a gene is asso-
ciated with gene suppression, while hypomethylation is linked
to gene expression; methylation within the gene body is also
associated with gene expression. Two next-generation sequencing
technologies have recently been developed for the analysis of gene
methylation – methylated DNA immunoprecipitation sequencing
(MeDIP)-seq, to detect methylated CpGs (26, 27), and MRE-seq,
to detect unmethylated CpGs (28). Integrative methodologies that
combine both MeDIP-seq and MRE-seq can differentiate hyper-
methylation, intermediate, and hypomethylation regions of DNA.
An integrative analysis of KLHL9 indicates that the CpG islands of
the KLHL9 promoter are highly hypomethylated (Figure 1). These
islands are highly conserved since they were found to be present in
virtually all cell types queried. Combining these data with ChIP-
seq histone modification data in the same tissues, we found that
hypomethylated CpGs of KLHL9 are occupied by significant levels
of trimethylated lysine 4 on histone H3 (H3K4me3) (Figure 1).
Two other hypomethylated regions in the type I IFN cluster, located
in the genomic region between IFNA2 and IFNA8,have relative low
levels of enrichment for H3K4me3 peaks (Figure 1). H3K4me3 is
a histone modification that accumulates at the transcription-start
site (TSS) of active genes and is believed to be important for tran-
scription activation. Loss of H3K4me3 occurs at TSSs and leads to
gene transcriptional inactivation as a result of promoter hyperme-
thylation. The occupancy of H3K4me3 in the promoter of KLHL9
may ensure the protection of CpG islands from methylation. In
contrast, the other two hypomethylated sites that are located quite
far from the TSSs of IFNA2 and IFNA8, may not be functional
for transcription. DNA methylation by RRBS from various cell
types, including B cells, failed to reveal strong methylation signals
in the IFNA gene cluster. One exception to this is that MeDIP-seq
defined methylation peaks were found to be distributed between
IFNA genes from brain tissue.
Thus far, data do not support that methylation is the likely
major mechanism by which IFNA gene expression is suppressed in
most non-IFN-producing cells. Further experimental studies will
be necessary to determine whether constructive hypomethylation,
as well as H3K4me3 occupancy, is important for regulating IFNA
gene transcription in IFN-producing cells such as monocytes,
and PDCs.
Chromatin structure
There are multiple IFNA and IFNB genomic regions that have open
chromatin structure in an evolutionally conserved pattern across
species and most human cell types. Since DNase I hypersensitive
sites (DHSs) reflect the local openness and accessibility of chro-
matin, chromatin structure or accessibility of IFNA clustering may
be similar among different cells. In general, hypersensitive sites are
found only in the chromatin of cells in which the associated gene
is being expressed, and do not occur when the gene is inactive.
Therefore, mapping DHSs within nuclear chromatin is a powerful
method of identifying genetic regulatory elements (29). However,
the distribution of DHSs in promoters and other gene regions of
similarly expressed genes differs among different chromosomes.
Furthermore, silenced genes have a more open chromatin struc-
ture than previously thought and DHSs in 3′-untranslated regions
(3′-UTRs) have been shown to negatively correlate with gene
expression levels (30), thus going against the standard dogma.
Bioinformatics analysis of DHSs in the IFN gene cluster between
different cell types revealed a highly conserved pattern (Figure 2);
FIGURE 1 | H3K4me3 peaks and methylation tracks on the type I IFN gene cluster. Members of the type I IFN gene cluster are shown and illustrated
proportionally according to Human (Homo sapiens) Genome hg19. H3K4me3 peaks and UCSC DNA methylation tracks are shown for a human B cell line.
FIGURE 2 | DNase I hypersensitivity sites in the type I IFN gene cluster
are highly conserved between cell types. Members of the type I IFN gene
cluster are shown and illustrated proportionally according to Human (Homo
sapiens) genome hg19. Cell lines and cell types analyzed are listed on the left
side. Short vertical lines below the gene track indicate the open chromatin
position marked by DNaseI hypersensitivity sites from
ENCODE/OpenChromatin (Duke University) for each cell type. Red lines
indicate the novel sites identified between cell types. The DNase I
hypersensitivity signal peaks for CD14+ monocytes are shown at the bottom
for reference to chromatin marks.
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however, we found additional DHSs in CD14+ monocytes that
can produce type I IFNs. We also found that CD34+ stem cells
have more DHSs close to promoters within the IFN gene cluster
(Figure 2). These data support the presence of unique cell-specific
chromatin structures which may play important regulatory roles
in the control of type I IFN expression.
Histone modification
Modifying the chromatin template at a particular gene locus can
also serve as an important mechanism of gene transcriptional
activation that exhibits cell-type specific expression patterns. The
functional importance of histone acetylation in type I IFN pro-
duction has been supported by studies that show increased IFN-β
expression in cells treated with histone deacetylase inhibitors, such
as Trichostatin A (TSA) (31), and decreased IFN-β expression
in murine macrophages where the binding of bromodomain-
containing BET (bromodomain and extraterminal) transcrip-
tional regulators to acetylated histones was inhibited (32). Di-
or tri-methylation of H3K9 is capable of suppressing gene expres-
sion not only passively, by inhibiting acetylation, but also actively,
by recruiting transcriptional repressors of the heterochromatin
protein 1 (HP1) family. We found that H3K9me2 occupancy at
IFN and ISG promoters is inversely correlated with gene expres-
sion. Furthermore, human MDDCs that are capable of producing
type I IFNs, as compared with human lung fibroblasts that do
not, show decreased H3K9me2 occupancy at the IFNB promoter.
In the absence of G9A, a methyltransferase for H3K9me2, non-
professional IFN-producing cells were shown to be converted into
potent IFN-β producers (33). Together, these data support the
importance of histone modifications in the regulation of type I
IFN expression.
H3K27me3, on the other hand, are found to be associated with
the repression of gene transcription in a cell-type specific manner.
Polycomb Repressive Complex 2 (PRC2) is a histone methyltrans-
ferase that catalyzes tri-methylation of Histone 3 at Lysine 27
(H3K27me3) (34). A detailed profile of H3K27me3 peaks reveal
that broad peaks at TSS are associated with transcriptional sup-
pression while skewed peaks up-stream of the TSS may not be
suppressive (35). Indeed, we found that IFNA regions in B cells,
which are incapable of producing IFN-α, are widely occupied with
H3K27me3, as shown by the substantive peaks found along the
gene cluster (Figure 3). In contrast, ChIP-seq data from monocytes
demonstrate that H3K27me3 peaks occupy some IFNA genes, such
as IFNA2, IFNA14, and intergenic regions between IFNA2 and
IFNA8, while the remaining IFNA genes were not suppressed by
H3K27me3.
As mentioned above, current dogma holds that H3K4me3 rep-
resents a chromatin landmark that is present at the TSS for genes
that are either actively transcribed or permissive for gene tran-
scription. However, H3K4me3 are not sufficient to license cells to
produce IFN-α. For example, multiple H3K4me3 occupancy peaks
can be identified in the IFN regulatory regions in B cells that do
not express IFN-α. A good comparison would be with PDCs, yet
the histone codes are not yet available for this cell type. In PDCs,
TLR-7 signaling quickly turns on transcription of IFNB, IFNA2,
IFNA8, and IFNA14 genes at 30 min post-stimulation with peak
levels being achieved at this time point. In comparison, peak levels
of IFNA5, IFNA6, IFNA10, IFNA13, and IFNA21 were observed
around 4 h post-stimulation (36). Based on our bioinformatics
analysis,we reason that transcriptional suppression by H3K27me3,
if it exists in PDCs in a pattern similar to that found in CD14+
monocytes, may not be functional in PDCs or can quickly be
replaced by H3K4me3 after TLR-7 activation. Alternatively, the
IFN gene cluster in PDCs may not have H3K27me3 markers. It is
not known whether chromatin change is necessary for IFNA tran-
scriptional activation or whether chromatin status is responsible
for differentially transcribed type I IFN genes. Further studies in
human PDCs will be required to address this.
Transcription factors regulating basal repression of IFNA gene
expression
The transcriptional repressor CTCF (11-zinc finger protein) or
CCCTC-binding factor is thought to regulate the 3-dimensional
(3D) structure of chromatin by binding strands of DNA together
and forming DNA loops (37). CTCF represses gene expression
by blocking the interaction between enhancers and promoters
(38). This phenomenon may serve as a chromatin barrier to
block the spread of heterochromatin structures and set boundaries
between active chromatin regions marked by histone H2A acetyl
Lys5 (H2AK5ac) and repressive regions marked by H3K27me3
(39). The cohesin complex, consisting of cohesion proteins SMC1,
SMC3, SCC3, and the α-kleisin SCC1, may contribute to CTCF-
mediated repression. Many CTCF/cohesin binding sites are located
at promoter regions suggesting a joint regulatory role for these
factors (40). Although most cohesin sites overlap with CTCF, a
significant proportion of each factor’s sites are independent of the
other, implying CTCF-independent functions of cohesin as well
as cohesin-independent CTCF functions. Bioinformatics analysis
of CTCF ChIP-seq data from ENCODE cell lines identified sev-
eral CTCF insulators that are basally located in the promoters and
intergenic regions of IFNA5, A1, A2, and A8 (Figure 4A). In gum
fibroblast cells (AG09319), we found five CTCF binding sites in
the region covering IFNA14, A17, A16, A10, A7, and A4. There is
only one CTCF/SMC3 binding site in the IFNB gene. The regula-
tory region of the IFNA2 gene contains two CTCF binding sites.
The second CTCF site yields co-binding with SMC3, suggesting
FIGURE 3 | H3K27me3 peaks on the type I IFN gene cluster. Members of the type I IFN gene cluster are shown and illustrated proportionally according to
Human (Homo sapiens) Genome hg19. H3K27me3 peaks were found along the entire region of the IFN gene cluster in the human B cell line GM128.
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FIGURE 4 | Differential occupancy for insulators CTCF and cohesin on the
IFNA8 and IFNB genes. (A)The genomic regions of IFNA8 and IFNA1 are
shown proportionally according to Human (Homo sapiens) Genome hg19.
CTCF (blue circles) and cohesin (purple circles) occupancy positions are
marked according to transcription factor ChIP-seq datasets from ENCODE.
Orange squares indicate positions enriched with H3K4Me3 signals. (B)The
genomic region of IFNB is shown with transcription factor binding sites from
the ENCODE database. Experimentally verified CTCF binding sites are shown
by the blue circles, with the darker shades of blue denoting signal intensity;
light blue – low intensity, dark blue – high intensity. IFN-stimulated response
elements (ISRE) are labeled with black squares. Peaks showing H3K4me3
signals are shown.
the cohesin complex may function in this IFN genomic region.
Based on these data, we speculate that CTCF may indeed function
as an IFNA suppressor and block promoter activation.
Within the IFNA gene cluster, we have yet to identify any other
TF in the ENCODE datasets that basally occupies the promoter
regions between TSSs and the proximal CTCF sites. In contrast,
multiple TFs, such as NF-κB and PU.1 (in B cells), do constitutively
occupy regions up-stream of CTCF sites that control individual
IFNA genes. CTCF binding sites are not conserved but cell-type
specific. While the majority of cells show CTCF occupancy up-
stream of the IFNA2 gene, binding is absent in fibroblast cells.
Similarly, at the IFNB promoter, CTCF binding was identified in
some B cells lines, HeLa cells, MCF-7, and osteoblast cells, but not
in any fibroblast cell lines or A549 lung carcinoma cells. Lack of
binding of this insulator may render fibroblast cells to produce
type I IFNs upon the appropriate stimulation, such as viral infec-
tion, thus supporting that CTCF binding to the IFNA gene may
be regulated. In this regard, dexamethasone treatment in A549
cell lines induces CTCF to bind to the IFNA8 promoter. Finally,
the discrepancy of CTCF binding patterns in Epstein–Barr virus
(EBV)-transformed B cell lines suggests that viral infection may
interfere with CTCF function. It is known that CTCF/cohesin
occupancy is essential for IFN-gamma (IFNg ) gene transcrip-
tion (41). Thus, this complex may have a similar function and
be important for regulating IFNB gene transcription via main-
taining the 3D chromatin structure of the IFNB locus in fibroblast
cells (Figure 4B). Based on these data, we propose that the DNA
regions in the IFN gene cluster that contain CTCF occupancy may
be subject to control by this factor to ensue IFNA transcription
during viral or viral-like challenges in IFN-producing cells. This
region may also be used as a landmark to demarcate the pro-
moter region that spans from a TSS to the CTCF binding sites and
enhancer regions located up-stream of CTCF binding site.
Transcription factors that regulate induction of IFNA gene
expression
Interferon regulatory factors, as their name suggests, have been
long known to regulate type I IFN gene expression (42). Of the
nine mammalian IRF family members currently identified to date,
IRF7 has garnered the most attention for its role in regulating IFNA
gene expression (3). IRF7 is highly expressed in human PDCs and
allows bypass of the classic autocrine feedback loop that is reg-
ulated by IFN-β (43). IRF7 was also shown to be required for
murine PDCs to produce an antiviral IFN immune response (44).
Similarly, IRF5 has been implicated in the regulation of type I IFN
gene expression (45). Early data in human cell lines revealed the
regulation of type I IFN genes and IFN-stimulated genes (ISGs)
by IRF5 in response to virus (46). Later data in mice supported
these findings. For example, splenic PDCs from mice lacking Irf5
were shown to produce less type I IFNs in response to virus
infection (47). IRF5 has also been recently reported to regulate
IFN-β production in myeloid dendritic cells downstream of the
mitochondrial antiviral-signaling protein (MAVS) (48). Further-
more, recent studies demonstrate that IRF5 and NF-κB p50 are
key co-regulators of IFN-β and IL-6 expression in TLR9-mediated
activation of human PDCs (49). Although both of these IRF
family members have been implicated as key regulators of IFN-α
production,no ChIP-seq data is available to support these findings.
Interestingly, data from the aforementioned STAT4/IRF5 ChIP-seq
datasets in PBMCs did not support the direct regulation of type I
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IFN expression by IRF5 since no peaks were detected in the IFN
gene cluster after immunoprecipitation with anti-IRF5 antibodies
(22). In this case, PBMCs were stimulated with either IFNa2 or SLE
immune complexes before immunoprecipitation with anti-IRF5
or anti-STAT4 antibodies. In the case of IRF7, a cursory review
of the literature and publicly available datasets indicate that no
ChIP-seq data is currently available for this TF. We have recently
performed IRF5 and IRF7 ChIP-seq in human PDCs stimulated
with virus. Our unpublished data indicate that these two TFs bind
to different regions in the IFNA gene cluster (Figure 5). These data
support the distinct and differential roles for IRF5 and IRF7 in type
I IFN gene regulation (45, 49). With regard to autoimmune dis-
eases such as SLE and SS that display a pathogenic type I IFN gene
signature, determination of the mechanisms by which these two
IRF family members cooperatively and distinctly regulate IFNA
subtype expression in the critical IFN-α producing cell types will
be important for the design of new therapeutic strategies targeting
these two factors.
CONCLUDING REMARKS
With the recent generation of large datasets in the public domain
from next-generation sequencing and DNA microarray experi-
ments, others and we have begun to perform detailed analyses of
cell-type specific gene signatures as well as identify distinct TFs
that differentially regulate these gene signatures in a cell type- and
disease-specific manner. This report describes a sample workflow
and method of integrative analysis to inspect, clean, and model
data from GEO and ENCODE with the goal of highlighting infor-
mation and knowledge discovery at the gene cluster level. We
demonstrate that this method can extract valuable information
including downstream pathway analysis, DNA methylation, chro-
matin structure, histone modification, and TF binding to a gene of
interest (in our case, type I IFNAs). This report summarizes data
from our bioinformatics analysis of the type I IFN gene cluster
FIGURE 5 | Differential binding of IRF5 and IRF7 to the IFNA2 gene in
human primary PDCs stimulated with virus. The genomic region of
IFNA2 is shown with IRF5 and IRF7 ChIP-seq peaks plotted according to
their enrichment positions. Briefly, human primary PDCs were stimulated
with Herpes simplex virus (HSV) for 4 h and cells cross-linked and harvested
for immunoprecipitations with anti-IRF5 or anti-IRF7 antibodies.
using data in the public domain and experimental unpublished
data from our lab (Tables 1 and 2). We have found that the genetic
landscape of the IFNA and IFNB genes are occupied by TF, such as
insulator CTCF and cohesin, that negatively regulate transcription,
as well as IRF5 and IRF7, that positively and distinctly regulate the
IFNA subtypes. This information can be used as a reference to
guide future experiments that focus on proving and/or disapprov-
ing these novel regulatory mechanisms that control type I IFN
expression. A detailed understanding of the factors controlling
type I IFN gene transcription will significantly aid in the identi-
fication and development of new therapeutic strategies targeting
the IFN pathway in autoimmune disease.
Table 1 | Results from computational pathway analysis of microarray
data sets.
Genes and
pathways
Ex vivo type
I IFN treatment
In SLE patients
IL-15 and its receptor
IL-15Rα
Up-regulated Up-regulated
IL-7 Up-regulated Up-regulated
CD59 Up-regulated Up-regulated
MAP kinase MAP kinase (ERK2) activity
at up-stream of STAT1,
MAP2K5, MAP2K5 are
up-regulated
Unknown
TLR pathway (TLR-3, 7,
1,TRAF/TANK, IRF4,
and IRF1)
Up-regulated TLR-7 up-regulateda
STAT STAT1 STAT1, STAT4
Apoptotic pathways Up-regulated caspase 1, 8,
and 10,TRAIL, FADD
Up-regulated
anti-apoptotic genes
including BIRC5
aIndicates data from Ref. (50).
The following list of genes and pathways were predicted to be active in PBMCs
treated with type I IFN ex vivo and in SLE patients.
Table 2 | Results from the computational analysis of ENCODE
next-generation sequencing data on the type I IFN gene cluster.
Epigenetic markers Factors that affect type I IFN gene cluster
Chromatin structure Monocytes display more DNase I
hypersensitivity sites within gene cluster
Methylation Methylation not found in non-IFN-producing
cells; hypomethylated CpG island identified
in cluster
Histone modification H3K4Me3, H3K27me3, H3K9me2
Conserved transcription
factor binding site
HMR conserved transcription factor binding
sites computed with the Transfac Matrix
Database (v7.0) identified ISRE sites
Transcription factors IRF5, IRF7
Insulator CTCF, SMC3, cohesin complex
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